ライフサイエンスコーパス: defibrillator

1 nization therapy or implantable cardioverter-defibrillator).

2 start CPR or retrieve an automated external defibrillator.

3 of the subcutaneous implantable cardioverter-defibrillator.

4 on with (n = 4,037) or without (n = 1,270) a defibrillator.

5 ify placement of an implantable cardioverter-defibrillator.

6 entive therapy, the implantable cardioverter defibrillator.

7 as a single chamber implantable cardioverter defibrillator.

8 primary prevention implantable cardioverter defibrillator.

9 nervation and implantation of a cardioverter-defibrillator.

10 thetic valves and less frequently pacemakers/defibrillators.

11 the optimal use of implantable cardioverter-defibrillators.

12 e of candidates for implantable cardioverter defibrillators.

13 use of publicly available automated external defibrillators.

14 ith advanced HF and implantable cardioverter-defibrillators.

15 primary prevention implantable cardioverter defibrillators.

16 een (68%) patients have received implantable defibrillators.

17 respectively) but less frequently pacemakers/defibrillators (1.5% vs. 10.5%; p < 0.001), and showed h

18 4 (25%) received an implantable cardioverter-defibrillator; 1 underwent cardiac transplantation; 2 ha

19 2) ICD Registry for implantable cardioverter-defibrillators (158,649 procedures performed in 1,715 ho

20 ation therapy (CRT) pacemakers (4%), and CRT defibrillators (17%), as well as abandoned leads (2%).

21 cemaker (58%) or an implantable cardioverter-defibrillator (42%) that was not considered to be MRI-co

22 , more secondary prevention indication for a defibrillator (64.9% vs 44.5%, p = 0.023), and more pre-

23 h men and women, but more so in women (e.g., defibrillator 8.6% vs. 16.6%; p < 0.0001).

24 CA occurrence may improve automated external defibrillator accessibility.

25 By probability rank, implantable cardiac defibrillator+ACE inhibitor or ARB+BB+mineralocorticoid

26 oid receptor antagonist, implantable cardiac defibrillator+ACE inhibitor or ARB+BB, and angiotensin r

27 tation of pacemaker/implantable cardioverter defibrillator, acute myocardial infarction, pulmonary em

28 g rhythms shockable by an automatic external defibrillator (AED), implantable cardioverter-defibrilla

29 Automated external defibrillators (AEDs) are often placed in areas of low r

30 pital cardiac arrest, but automated external defibrillators (AEDs) are rarely available for bystander

31 Installation of automated external defibrillators (AEDs) in schools has been associated wit

32 despread dissemination of automated external defibrillators (AEDs).

33 d rabbit hearts (n=22) and terminated with a defibrillator after 6 minutes.

34 The randomized DAPA trial (Defibrillator After Primary Angioplasty) aimed to evalua

35 otentially saved by implantable cardioverter-defibrillators, all de novo implantations for secondary

36 350 (58%) patients, implantable cardioverter-defibrillators alone in 25 (4%) patients, left cardiac s

37 nonselective post-mortem CIED (pacemaker or defibrillator) analysis in this setting are lacking.

38 drug continuation, implantable cardioverter defibrillator and cardiac resynchronization therapy impl

39 ients randomized to implantable cardioverter-defibrillator and CRT with defibrillator (CRT-D), respec

40 le defibrillator OR implantable cardioverter defibrillator AND non-ischemic cardiomyopathy.

41 patients with prior implantable cardioverter-defibrillator and those randomized only to medical thera

42 primary prevention implantable cardioverter-defibrillator and widening QRS.

43 al effectiveness of implantable cardioverter defibrillators and understand why these devices should b

44 esuscitation and applying automated external defibrillator) and ALS ambulances (medicalized team prov

45 tion, implantation of an implantable cardiac defibrillator, and mitral or tricuspid valve repair or r

46 c resynchronization implantable cardioverter-defibrillator, and VT storm despite greater antiarrhythm

47 makers, 17 cardiac resynchronization therapy defibrillators, and 2 cardiac resynchronization therapy

48 ponder systems, access to automated external defibrillators, and innovations to match resuscitation r

49 Pharmacotherapy, implantable cardioverter-defibrillators, and left cardiac sympathetic denervation

50 entions are available, including medication, defibrillators, and lifestyle modifications.

51 tion of cardiac devices, such as pacemakers, defibrillators, and mechanical circulatory support.

52 the placement of an implantable cardioverter-defibrillator are based on an estimate of a patient's ri

53 Implantable cardioverter-defibrillators are indicated for prevention of secondary

54 Patients who have pacemakers or defibrillators are often denied the opportunity to under

55 Implantable cardioverter-defibrillators are used to prevent sudden cardiac death

56 tery depletion, as well as a hard reset in a defibrillator as a result of cold exposure.

57 with advanced HF with an implantable cardiac defibrillator at high risk of death.

58 Patients who had an implantable cardioverter-defibrillator at the time of trial enrollment were exclu

59 en rescuers and providing automated external defibrillators at the scene hold the promise of improvin

60 ng for all dialysis clinic staff and on-site defibrillator availability, but the extent of staff invo

61 initiated CPR in 81.4% of events and applied defibrillators before EMS arrival in 52.3%.

62 sting literature on implantable cardioverter defibrillators, biventricular pacemakers, mechanical cir

63 Although an implantable cardioverter-defibrillator can save lives in individuals with this di

64 terion to determine implantable cardioverter defibrillator candidacy.

65 , who are potential implantable cardioverter defibrillator candidates, treated with dofetilide as an

66 <=35% without prior implantable cardioverter defibrillator, cardiac resynchronization therapy, or AF

67 ad better survival when receiving CRT with a defibrillator compared with those who received CRT witho

68 However, the efficacy of CRT with a defibrillator (CRT-D) may be modified after the developm

69 hospital characteristics associated with CRT defibrillator (CRT-D) use and (2) determine the extent o

70 n all patients and in patients with CRT with defibrillator (CRT-D) versus ICD.

71 able cardioverter-defibrillator and CRT with defibrillator (CRT-D), respectively (P=0.209).

72 ts eligible for implantation with a CRT with defibrillator (CRT-D).

73 receiving cardiac resynchronization therapy defibrillators (CRT-D) have a very wide (>/=180 ms) QRS

74 3%; cardiac resynchronization therapy with a defibrillator [CRT-D], 38.9%).

75 rvention to Improve Implantable Cardioverter-Defibrillator Deactivation Conversations [WISDOM]; NCT01

76 rs or cardiac resynchronization therapy with defibrillators demonstrated a significant reduction of a

77 otential partnerships for automated external defibrillator deployment in public-access defibrillator

78 ng specific locations for automated external defibrillator deployment incorporating operating hours a

79 system blockers alone or in combination with defibrillator device therapy have robust evidence for a

80 e, ischemic disease 39%), 74.3% received CRT-defibrillator devices, using mainly quadripolar LV leads

81 sts (arrhythmic death or implantable cardiac defibrillator discharge for ventricular fibrillation or

82 ventricular tachycardia, implantable cardiac defibrillator discharge, and sudden cardiac arrest, 43%)

83 rienced appropriate implantable cardioverter-defibrillator discharges, 2 underwent heart transplants,

84 rdiomyopathy (DCM), implantable cardioverter-defibrillators do not increase longevity.

85 rimary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD), a prospective, investigato

86 death, appropriate implantable cardioverter-defibrillator firing, resuscitated cardiac arrest, and h

87 events (appropriate implantable cardioverter-defibrillator firings and arrhythmic sudden cardiac deat

88 nts with DCM for an implantable cardioverter-defibrillator for primary prevention purposes.

89 (n=204) eligible for an implantable cardiac defibrillator for the primary prevention of sudden cardi

90 hronization therapy implantable cardioverter defibrillator for the treatment of heart failure are mor

91 Women receiving implantable cardioverter defibrillators for primary prevention of sudden cardiac

92 well as the role of implantable cardioverter defibrillators for primary prevention.

93 d with subcutaneous implantable cardioverter-defibrillators from 2 hospitals between 2009 and 2016 we

94 in OHCA patients where an automated external defibrillator had been used by nonemergency medical serv

95 As the population of patients with implanted defibrillators has grown, an increasing number of patien

96 mpared with those who received CRT without a defibrillator (hazard ratio for mortality adjusted on pr

97 In patients with implantable cardioverter-defibrillators, healthcare utilization (HCU) and expendi

98 tment for mitral regurgitation and pacemaker/defibrillator (HR: 0.35; 95% CI: 0.23 to 0.54; p < 0.000

99 enefits of CRT over implantable cardioverter-defibrillator (ICD) alone.

100 implantation of an implantable cardioverter defibrillator (ICD) and include promotion of shared deci

101 0 days after MI for implantable cardioverter-defibrillator (ICD) candidacy.

102 VTs based on stored implantable cardioverter-defibrillator (ICD) electrograms.

103 Patients with an implantable cardioverter defibrillator (ICD) had tachycardia therapies disabled d

104 fit of prophylactic implantable cardioverter defibrillator (ICD) implantation in early selected high-

105 lue of prophylactic implantable cardioverter-defibrillator (ICD) implantation to prevent SCD is uncer

106 may be prevented by implantable cardioverter-defibrillator (ICD) implantation, but patient stratifica

107 ely to benefit from implantable cardioverter-defibrillator (ICD) implantation.

108 Patients undergoing implantable cardioverter-defibrillator (ICD) implantations have high rates of lon

109 revention use of an implantable cardioverter-defibrillator (ICD) improves survival in patients with c

110 ival benefit of the implantable cardioverter defibrillator (ICD) in males with arrhythmogenic right v

111 combination with an implantable cardioverter defibrillator (ICD) in patients who are eligible for thi

112 The benefit of an implantable cardioverter-defibrillator (ICD) in patients with symptomatic systoli

113 Data evaluating the implantable cardioverter defibrillator (ICD) in this patient population remain sc

114 Implantable cardioverter-defibrillator (ICD) indications for primary prevention i

115 Penetration of the implantable cardioverter-defibrillator (ICD) into this patient population over th

116 The implantable cardioverter-defibrillator (ICD) is effective for preventing sudden d

117 he subcutaneous (S) implantable cardioverter-defibrillator (ICD) is safe and effective for sudden car

118 The implantable cardioverter-defibrillator (ICD) is the standard therapy to prevent s

119 For the former, an implantable cardioverter-defibrillator (ICD) is typically required due to an elev

120 d or malfunctioning implantable cardioverter-defibrillator (ICD) lead may have the lead either abando

121 T-D were matched to implantable cardioverter-defibrillator (ICD) patients without CRT despite having

122 Implantable cardioverter-defibrillator (ICD) recipients require close follow-up t

123 cular Data Registry implantable cardioverter-defibrillator (ICD) registry data between 2010 and 2013,

124 edish Pacemaker and Implantable Cardioverter-Defibrillator (ICD) Registry.

125 educe the burden of implantable cardioverter-defibrillator (ICD) shocks in small series of patients w

126 ce (MR)-conditional implantable cardioverter defibrillator (ICD) systems have become available.

127 had a pacemaker or implantable cardioverter-defibrillator (ICD) that was "non-MRI-conditional" (i.e.

128 knowledge, whether implantable cardioverter defibrillator (ICD) therapy improves survival for these

129 predict appropriate implantable cardioverter defibrillator (ICD) therapy in ischemic cardiomyopathy (

130 21 had appropriate implantable cardioverter-defibrillator (ICD) therapy terminating potentially leth

131 e, placebo drug, or implantable cardioverter-defibrillator (ICD) therapy.

132 andomized trials on implantable cardioverter-defibrillator (ICD) use for primary prevention of sudden

133 The subcutaneous implantable cardioverter-defibrillator (ICD) was designed to avoid complications

134 zed to CRT-D versus implantable cardioverter defibrillator (ICD) were compared within the groups of p

135 efibrillator (AED), implantable cardioverter-defibrillator (ICD), or wearable cardioverter-defibrilla

136 In patients with an implantable cardioverter-defibrillator (ICD), shocks are associated with increase

137 rrhythmic events in implantable cardioverter-defibrillator (ICD)-eligible cardiomyopathy patients.

138 on in patients with implantable cardioverter-defibrillator (ICD).

139 val benefit with an implantable cardioverter-defibrillator (ICD).

140 ly effective prevention is implantation of a defibrillator (ICD).

141 uced by means of an implantable cardioverter-defibrillator (ICD).

142 dia pacing (ATP) in implantable cardioverter-defibrillators (ICD) decreases patient shock burden but

143 Among patients with implantable defibrillators (ICD), use of remote patient monitoring (

144 Older recipients of implantable cardioverter-defibrillators (ICDs) are at increased risk for short-te

145 Background Implantable cardioverter-defibrillators (ICDs) are indicated in patients with lef

146 ac death (SCD), and implantable cardioverter-defibrillators (ICDs) are the mainstay of therapy.

147 tic implantation of implantable cardioverter defibrillators (ICDs) experiences malignant arrhythmias.

148 on the efficacy of implantable cardioverter defibrillators (ICDs) for primary prevention of sudden c

149 he effectiveness of implantable cardioverter-defibrillators (ICDs) for primary prevention of sudden d

150 Clinical trials of implantable cardioverter-defibrillators (ICDs) for secondary prevention of sudden

151 Implantable cardioverter-defibrillators (ICDs) have a role in preventing cardiac

152 Although implantable cardioverter-defibrillators (ICDs) reduce sudden death, these patient

153 on in patients with implantable cardioverter-defibrillators (ICDs), but ventricular proarrhythmia is

154 egic programming of implantable cardioverter-defibrillators (ICDs), including faster detection rates,

155 d 160 patients with implantable cardioverter defibrillators (ICDs), of whom 94 patients had 24- to 48

156 among recipients of implantable cardioverter-defibrillators (ICDs).

157 patients receiving implantable cardioverter-defibrillators (ICDs).

158 VT in patients with implantable cardioverter-defibrillators (ICDs).

159 patients receiving implantable cardioverter-defibrillators (ICDs).

160 In the subcutaneous implantable cardioverter-defibrillator IDE study (Investigational Device Exemptio

161 dy of patients with implantable cardioverter-defibrillators identified from commercial and Medicare s

162 or initial cardiac resynchronization therapy defibrillator implant.

163 pitation (P=0.004), implantable cardioverter defibrillator implantation (P=0.021), lower left ventric

164 Fifteen subjects admitted for defibrillator implantation and ejection fraction <=35% o

165 n patients undergoing de novo or upgrade CRT defibrillator implantation at 3 implant centers in Germa

166 r complications, bleeding, and new pacemaker/defibrillator implantation demonstrated no significant d

167 n cardiac death, or implantable cardioverter-defibrillator implantation in a cohort of 2622 stable pa

168 lication related to implantable cardioverter defibrillator implantation in comparison with men.

169 recommendations for implantable cardioverter-defibrillator implantation in patients with known or sus

170 vival benefit after implantable cardioverter-defibrillator implantation in patients with nonischemic

171 recommendations for implantable cardioverter-defibrillator implantation in these patients are in the

172 se and indication for implanted cardioverter-defibrillator implantation independently of particle rad

173 best candidates for implantable cardioverter defibrillator implantation is one of the most challengin

174 , and the effect of implantable cardioverter-defibrillator implantation on all-cause mortality was no

175 mined 1,214 MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchron

176 n the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchron

177 n the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronizati

178 AND PARTICIPANTS: The Multicenter Automatic Defibrillator Implantation Trial-Chemotherapy-Induced Ca

179 n the MADIT-RIT study (Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Th

180 ting at the time of implantable cardioverter-defibrillator implantation was performed to evaluate the

181 ime of subcutaneous implantable cardioverter-defibrillator implantation without the need to induce ve

182 erwent subcutaneous implantable cardioverter-defibrillator implantation, 282 patients were included i

183 o associated with higher rates of mortality, defibrillator implantation, VT ablation (adjusted HR: 4.

184 lect candidates for implantable cardioverter-defibrillator implantation.

185 eath, and effect of implantable cardioverter-defibrillator implantation.

186 ho may benefit from implantable cardioverter defibrillator implantation.

187 ting indication for implantable cardioverter defibrillator implantation.

188 tients with DCM for implantable cardioverter-defibrillator implantation.

189 n the indication of implantable cardioverter-defibrillator implantation.

190 hysiological evaluation that could result in defibrillator implantation.

191 of sudden cardiac death undergo cardioverter-defibrillator implantation; in patients with severe symp

192 orse after upgrade compared with de novo CRT defibrillator implantations (hazard ratio, 1.65; 95% con

193 containing data on implantable cardioverter-defibrillator implantations from all implanting sites th

194 illator or cardiac resynchronization therapy defibrillator implanted.

195 be averted by implantation of a cardioverter-defibrillator in appropriate high-risk patients.

196 ted the ICD2 trial (Implantable Cardioverter-Defibrillator in Dialysis Patients), a prospective, rand

197 mmend the use of an implantable cardioverter defibrillator in patients with dilated cardiomyopathy fo

198 nts with dual-chamber implanted cardioverter-defibrillators in Boston, Massachusetts between Septembe

199 itral regurgitation, and implantable cardiac defibrillators in patients with more severe left ventric

200 Accordingly, placement of automated external defibrillators in the community as part of a public acce

201 e Efficacy of ICDs [Implantable Cardioverter Defibrillators] in Patients With Non-Ischemic Systolic H

202 ts with primary versus secondary prophylaxis defibrillator indications.

203 ures, and pacemaker/implantable cardioverter-defibrillator insertion and repair.

204 decision making for implantable cardioverter defibrillator insertion.

205 er 1000), pacemaker/implantable cardioverter-defibrillator insertions (1.6 to 4.4 per 1000), nuclear

206 death, appropriate implantable cardioverter-defibrillator intervention, and aborted cardiac arrest w

207 s and inappropriate implantable cardioverter defibrillator interventions.

208 arly defibrillation by an automated external defibrillator is the most important intervention for pat

209 Implantable cardioverter defibrillator is the only proven lifesaving therapy; how

210 Access to pacemakers and defibrillators is problematic in places with limited res

211 Several defibrillator leads have been recalled due to early lead

212 Confirming the safety of contemporary defibrillator leads is essential to optimizing treatment

213 ere recorded in the implantable cardioverter-defibrillator logs the 6 months preceding ablation.

214 Need for implantable defibrillator (LVEF <=30%) was reduced in the high MI/PC

215 of the subcutaneous implantable cardioverter-defibrillator may offer procedural and cosmetic advantag

216 ization therapy and implantable cardioverter-defibrillators may be required to prevent life-threateni

217 synchronisation and implantable cardioverter-defibrillators; neurohumoral modification by baroreflex

218 d into 3 groups according to who applied the defibrillator: nondispatched lay first responders, profe

219 The CRT-D versus implantable cardioverter-defibrillator-only risk for first and subsequent HHF was

220 d receptor antagonist to implantable cardiac defibrillator+optimal pharmacological combination therap

221 thy, presence/absence of implantable cardiac defibrillator or cardiac resynchronization therapy and e

222 er index hospitalization with a cardioverter-defibrillator or cardiac resynchronization therapy defib

223 October 31, 2016, for the terms implantable defibrillator OR implantable cardioverter defibrillator

224 alone or in addition to implantable cardiac defibrillators or cardiac resynchronization therapy with

225 xcluded if they had implantable cardioverter defibrillators or permanent pacemakers.

226 CI, 1.17-1.25]), no implantable cardioverter defibrillator (OR, 1.46 [95% CI, 1.34-1.55]), lower LVEF

227 acked by indwelling implantable cardioverter defibrillators) or any reduction in PVC burden (as measu

228 Patients with pacemakers/defibrillators, organic valve disease, or previous valve

229 ct of an additional implantable cardioverter-defibrillator over CRT, according to underlying heart di

230 n = 5, 17.2%), and urgent implantable cardio-defibrillator/permanent pacemaker placements (n = 8; 27.

231 ascularization, or urgent implantable cardio-defibrillators/permanent pacemaker placements within 12

232 Efforts to guide automated external defibrillator placement for out-of-hospital cardiac arre

233 2 patients and new implantable cardioverter-defibrillator placement in 2.

234 proximately 130 000 implantable cardioverter defibrillator placements at a cost of >$3 billion but on

235 techniques, public access automated external defibrillator programs, analysis of rhythm during chest

236 al defibrillator deployment in public-access defibrillator programs.

237 e patients from the Implantable Cardioverter Defibrillator Registry (January 1, 2005, through April 3

238 of the subcutaneous implantable cardioverter defibrillator (S-ICD) in the United States have not been

239 ge for subcutaneous implantable cardioverter-defibrillator (S-ICD) screening.

240 The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to defibrillate vent

241 Subcutaneous implantable cardioverter-defibrillator shock efficacy is associated with system p

242 rhythmia, sudden cardiac arrest, appropriate defibrillator shock, or death in either group.

243 After implantable cardioverter-defibrillator shock, related HCU was common, with 1 in 3

244 eath or appropriate implantable cardioverter-defibrillator shock.

245 s observed for both implantable cardioverter defibrillator shocks and antitachycardia pacing.

246 p 1 experienced multiple implantable cardiac defibrillator shocks for recurrent VT/VF episodes.

247 rdia requiring >/=2 implantable cardioverter-defibrillator shocks occurred in 13 patients, including

248 Implantable cardioverter-defibrillator shocks seem to trigger a cascade of health

249 st, and appropriate implantable cardioverter-defibrillator shocks) was 0.84 per 1000 HCM person-years

250 llation-terminating implantable cardioverter-defibrillator shocks, and sudden cardiac death.

251 rved in transvenous implantable cardioverter-defibrillator studies.

252 , inadequate coil depth, and a lower rate of defibrillator success.

253 ommon among patients undergoing pacemaker or defibrillator surgery.

254 cemaker or a legacy implantable cardioverter-defibrillator system.

255 in CPR and in the use of automated external defibrillators, teaching first responders about team-bas

256 eived a resterilized and reused pacemaker or defibrillator, the incidence of infection or device-rela

257 Compared with recipients of defibrillators, the excess mortality in patients who did

258 ined as appropriate implantable cardioverter defibrillator therapies or on the basis of ECG-documente

259 est, 40 appropriate implantable cardioverter defibrillator therapies).

260 dence), appropriate implantable cardioverter-defibrillator therapy (5 studies; n=361; hazard ratio, 1

261 to be referred for implantable cardioverter defibrillator therapy despite current guideline recommen

262 ity and appropriate implantable cardioverter-defibrillator therapy in ischemic cardiomyopathy.

263 ell recognized that implantable cardioverter-defibrillator therapy is associated with both short- and

264 action (LVEF) and an indication for internal defibrillator therapy is controversial.

265 th, and appropriate implantable cardioverter defibrillator therapy was noted.

266 primary prevention implantable cardioverter-defibrillator therapy, as opposed to those with ICM.

267 death, appropriate implantable cardioverter-defibrillator therapy, resuscitated cardiac arrest, and

268 atients receiving de novo versus upgrade CRT defibrillator therapy.

269 Implantable cardioverter-defibrillator therapy.

270 ion of patients for implantable cardioverter defibrillator therapy.

271 ity from successful implantable cardioverter defibrillator therapy.

272 rest or appropriate implantable cardioverter defibrillator therapy.

273 were suggested for implantable cardioverter-defibrillator therapy.

274 t from prophylactic implantable cardioverter-defibrillator therapy.

275 pacing and implantation of internal cardiac defibrillators to prevent sudden death.

276 with single-chamber implantable cardioverter defibrillators to record ventricular arrhythmias (VAs) w

277 ovide tested and resterilized pacemakers and defibrillators to underserved nations; a prospective reg

278 urse content (63% perform automated external defibrillator training), instructor (47% used CPR-certif

279 c life support, including automated external defibrillator training; measuring implementation and per

280 SCD, sustained, or implantable cardioverter-defibrillator treated ventricular tachycardia >250 beats

281 ically unstable, or implantable cardioverter-defibrillator treated ventricular tachycardia; or aborte

282 ardiac death or (2) implantable cardioverter defibrillator-treated or hemodynamically unstable VTA.

283 essment may improve implantable cardioverter-defibrillator treatment decisions.

284 hyarrhythmias was 6:1, similar to randomized defibrillator trials in other cardiomyopathies.

285 osis of CPVT and an implantable cardioverter-defibrillator underwent a baseline exercise test while r

286 about team-based CPR (eg, automated external defibrillator use and high-performance CPR), and instruc

287 overall association between staff-initiated defibrillator use and outcomes, but there was a nonsigni

288 lmonary resuscitation and automated external defibrillator use were positively correlated with both o

289 P<0.01) but neither implantable cardioverter-defibrillator utilization nor ventricular arrhythmia var

290 all mortality (censored at implantation of a defibrillator, ventricular assist device, or cardiac tra

291 Implantation of an implantable cardioverter-defibrillator was considered but was ultimately contrain

292 , and the effect of implantable cardioverter-defibrillator was not modified by the duration of HF.

293 ss mortality in patients who did not receive defibrillators was related to sudden cardiac death in 8.

294 RT-D, compared with implantable cardioverter-defibrillator, was associated with a significant reducti

295 efibrillator (ICD), or wearable cardioverter-defibrillator (WCD).

296 syndrome patients having implantable cardiac defibrillator were enrolled: 63 (group 1) having documen

297 ation of a cardiac resynchronization therapy defibrillator were randomly assigned, in a 1:1 ratio, to

298 s likely to benefit from implantable cardiac defibrillators, which have no impact on nonsudden cardia

299 ll, 85% received pacemakers and 15% received defibrillators, with one (55.5%), two (38.8%), or three

300 a pacemaker with an implantable cardioverter defibrillator without asynchronous pacing capability.